Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.

Leotta S, Pirosa MC, Markovic U, Scalise L, Bulla A, Sapienza G, Di Giorgio MA, Martino EA, Curto Pelle A, Leotta V, Milone G, Cupri A, Vaddinelli D, Villari L, Conticello C, Milone G.

Chemotherapy. 2019;64(2):110-114. doi: 10.1159/000502473. Epub 2019 Sep 18.

PMID:
31533095
2.

Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.

Pirosa MC, Leotta S, Cupri A, Stella S, Martino EA, Scalise L, Sapienza G, Calafiore V, Mauro E, Spadaro A, Vigneri P, Di Raimondo F, Milone G.

Chemotherapy. 2018;63(4):220-224. doi: 10.1159/000492941. Epub 2018 Oct 29.

3.

Steroid treatment of acute graft-versus-host disease grade I: a randomized trial.

Bacigalupo A, Milone G, Cupri A, Severino A, Fagioli F, Berger M, Santarone S, Chiusolo P, Sica S, Mammoliti S, Sorasio R, Massi D, Van Lint MT, Raiola AM, Gualandi F, Selleri C, Sormani MP, Signori A, Risitano A, Bonifazi F; Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Haematologica. 2017 Dec;102(12):2125-2133. doi: 10.3324/haematol.2017.171157. Epub 2017 Sep 29.

4.

High BCR-ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib.

Vigneri P, Stagno F, Stella S, Cupri A, Forte S, Massimino M, Antolino A, Siragusa S, Mannina D, Impera SS, Musolino C, Malato A, Mineo G, Tomaselli C, Murgano P, Musso M, Morabito F, Molica S, Martino B, Manzella L, Müller MC, Hochhaus A, Raimondo FD.

Clin Cancer Res. 2017 Dec 1;23(23):7189-7198. doi: 10.1158/1078-0432.CCR-17-0962. Epub 2017 Sep 19.

5.

Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.

Milone G, Martino M, Leotta S, Spadaro A, Zammit V, Cupri A, Avola G, Camuglia MG, Di Marco A, Scalzulli P, Morelli M, Olivieri A, Tripepi G.

Leuk Lymphoma. 2018 Jan;59(1):42-48. doi: 10.1080/10428194.2017.1324161. Epub 2017 Jun 2.

PMID:
28573902
6.

Acute GVHD after allogeneic hematopoietic transplantation affects early marrow reconstitution and speed of engraftment.

Milone G, Camuglia MG, Avola G, Di Marco A, Leotta S, Cupri A, Spina P, Romano A, Spina E, Azzaro MP, Berritta D, Parisi M, Tripepi G.

Exp Hematol. 2015 Jun;43(6):430-8.e1. doi: 10.1016/j.exphem.2015.02.002. Epub 2015 Feb 20.

PMID:
25704053
7.

Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.

Milone G, Leotta S, Cupri A, Fauci AL, Spina P, Parisi M, Berritta D, Tripepi G.

Bone Marrow Transplant. 2014 Sep;49(9):1193-7. doi: 10.1038/bmt.2014.140. Epub 2014 Jul 7.

PMID:
25000456
8.

Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.

Milone G, Martino M, Spadaro A, Leotta S, Di Marco A, Scalzulli P, Cupri A, Di Martina V, Schinocca E, Spina E, Tripepi G.

Br J Haematol. 2014 Jan;164(1):113-23. doi: 10.1111/bjh.12606. Epub 2013 Oct 21.

PMID:
24138497
9.

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation.

Giallongo C, La Cava P, Tibullo D, Barbagallo I, Parrinello N, Cupri A, Stagno F, Consoli C, Chiarenza A, Palumbo GA, Di Raimondo F.

BMC Cancer. 2013 Feb 5;13:60. doi: 10.1186/1471-2407-13-60.

10.

Infliximab therapy in hematologic malignancies: handle with care.

Stagno F, Vigneri P, Cupri A, Vitale SR, Di Raimondo F.

Haematologica. 2012 Aug;97(8):e26; author reply e27. doi: 10.3324/haematol.2012.067934. No abstract available.

11.

Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment.

Stagno F, Vigneri P, Cupri A, Stella S, Di Raimondo F.

Leuk Res. 2012 Sep;36(9):1208-9. doi: 10.1016/j.leukres.2012.05.024. Epub 2012 Jun 20. No abstract available.

PMID:
22726921
12.

Diagnosis of blastic phase of chronic myeloid leukemia.

Stagno F, Vigneri P, Cupri A, Vitale SR, Di Raimondo F.

Acta Haematol. 2012;127(4):198. doi: 10.1159/000337267. Epub 2012 Mar 21. No abstract available.

PMID:
22441204
13.

Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia.

Stagno F, Vigneri P, Consoli ML, Cupri A, Stella S, Tambè L, Massimino M, Manzella L, Di Raimondo F.

Acta Haematol. 2012;127(1):7-9. doi: 10.1159/000330607. Epub 2011 Oct 5. No abstract available.

PMID:
21986290
14.

Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.

Stagno F, Vigneri P, Del Fabro V, Stella S, Cupri A, Massimino M, Consoli C, Tambè L, Consoli ML, Antolino A, Di Raimondo F.

Acta Oncol. 2010 May;49(4):506-8. doi: 10.3109/02841861003660031.

PMID:
20331405
15.

Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.

Stagno F, Vigneri P, Del Fabro V, Stella S, Massimino M, Berretta S, Cupri A, Consoli C, Messina L, Tirrò E, Messina A, Di Raimondo F.

Leuk Res. 2009 Sep;33(9):e157-8. doi: 10.1016/j.leukres.2009.03.040. Epub 2009 Apr 29. No abstract available.

PMID:
19406471
16.

Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.

Conticello C, Adamo L, Vicari L, Giuffrida R, Iannolo G, Anastasi G, Caruso L, Moschetti G, Cupri A, Palumbo GA, Gulisano M, De Maria R, Giustolisi R, Di Raimondo F.

Acta Haematol. 2008;120(1):19-30. doi: 10.1159/000151511. Epub 2008 Aug 21.

PMID:
18716397

Supplemental Content

Support Center